文献速递烧伤创面修复

皮肤细胞悬液自体移植作为烧伤与创面治疗的循证创新:二十年全球证据的系统综述

Skin cell suspension autograft as an evidence-based innovation in burn and wound treatment: A systematic review of global evidence across two decades.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2026-08-07

27项对照研究显示SCSA持续减少供皮区,61%愈合结局优于对照、39%相当,疼痛与美学结局多倾向SCSA,安全性总体相似但经济结局不一。

要点

  • SCSA可单独或联合自体移植用于烧伤、手术创面、创伤、炎症及慢性创面。
  • 对照研究中SCSA持续减少供皮区面积,多数愈合结局不劣于或优于对照。
  • 安全性与对照总体相似,住院时间与资源利用可能降低但证据不一致。

核心结论

  • 全球证据支持SCSA作为促进表皮覆盖的多用途创面治疗方式。
  • 对照研究中的临床与经济获益支持SCSA作为烧伤与创面治疗的循证创新。

研究设计与样本

  • 对评估SCSA与对照治疗的比较研究提取临床、安全与卫生经济学结局。

主要发现

  • SCSA单独或联合自体移植用于烧伤、手术创面、创伤、炎症性疾病及慢性创面。
  • 27项比较研究中,SCSA持续减少供皮皮肤,61%的愈合结局倾向SCSA,39%报告结局相当。
  • 疼痛与美学结局更常倾向SCSA,安全性结局总体相似,部分研究倾向对照。
  • 卫生经济学结局提示住院时间与资源利用可能降低,但各研究结果不一。

临床怎么用

  • 可将SCSA作为减少供皮区负担并促进上皮化的点即时(point-of-care)创面处理选择。
  • 适用于烧伤、手术创面、创伤、炎症及慢性创面等多种病因的创面覆盖。
  • 决策时应结合本研究异质性大、非随机数据为主及缺乏定量合并分析的局限。

局限性

  • 研究设计异质、结局报告不一致。
  • 以非随机数据为主。
  • 未进行正式定量分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin cell suspension autograft (SCSA) is a point-of-care approach to wound management facilitating epithelialization while reducing burden associated with conventional autografting. Despite growing clinical use of SCSA across diverse wound etiologies, the global clinical evidence describing its use has not yet been comprehensively synthesized. METHODS: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) guidelines to identify studies between January 2000 and December 2024 reporting clinical use of SCSA for wound closure. Data on patient demographics, wound characteristics, and treatment methods were extracted. Clinical, safety, and health economic outcomes were extracted for comparative studies evaluating SCSA against control treatments. RESULTS: Ninety-nine studies across 13 countries were included. Across the overall dataset, SCSA was used alone or in combination with autografting for burns, surgical wounds, traumatic injuries, inflammatory conditions, and chronic wounds. Among comparative studies (n=27), SCSA consistently reduced donor skin, and healing outcomes favored SCSA in 61%, while 39% reported equivalent outcomes. Pain and esthetic outcomes more frequently favored SCSA, while safety outcomes were generally similar, with some studies favoring comparators. Health-economic outcomes suggested potential reductions in length of stay and resource utilization, although findings were variable across studies. CONCLUSION: The available global evidence supports SCSA as a versatile modality for supporting epidermal coverage across wound types and clinical contexts. However, the findings should be interpreted in the context of the limitations of this review, which include heterogenous study designs, variable outcome reporting, predominance of non-randomized data, and the absence of a formal quantitative analysis. Nevertheless, the demonstrated clinical and economic benefits in comparative studies reinforce the role of SCSA as an evidence-based innovation for burn and wound treatment.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Saraswat AB, Rawlins JM, Carter JE, et al. Skin cell suspension autograft as an evidence-based innovation in burn and wound treatment: A systematic review of global evidence across two decades. J Plast Reconstr Aesthet Surg. 2026. PMID: 42594517. doi:10.1016/j.bjps.2026.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。